Literature DB >> 17597509

Armillariella mellea shows anti-inflammatory activity by inhibiting the expression of NO, iNOS, COX-2 and cytokines in THP-1 cells.

Shu-Jing Wu1, Jenn-Yi Tsai, Min-Nan Lai, Lean-Teik Ng.   

Abstract

Armillariella mellea (AM), also known as Mi-Huan-Ku, a popular medicinal fungus used in the traditional Chinese medicine for treating headache, neurasthenia and insomnia. In the present study, our aim was to determine the effects of aqueous (AAM) and ethanol (EAM) extracts of A. mellea on lipopolysaccharide (LPS)-induced inflammatory response by measuring the inducible nitric oxide synthase (iNOS), cyclooxygenase-1 and -2 (COX-1 and COX-2) protein expression, cytokines (TNF-alpha, IL-4 and IL-8) formation, nitric oxide (NO) release and prostaglandin (PGE(2)) production in human monocytic (THP-1) cells. At concentration of 100 microg/ml, EAM, but not AAM, effectively protected against LPS-induced cell death in THP-1 cells. At concentrations of 10 approximately 100 microg/ml, EAM showed a potent anti-inflammatory activity as demonstrated by a dose-dependent inhibition of LPS (1 microg/ml)-induced release of NO and PGE(2), and significantly decreased the transcription of proinflammatory cytokines. EAM at 100 mug/ml significantly blocked the LPS induction of iNOS and COX-2 expression, but not COX-1. Therefore, the protective effect of EAM against LPS-induced inflammatory mediators release could explain, at least in part, its effectiveness in alleviating certain inflammatory related diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597509     DOI: 10.1142/S0192415X07005028

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  2 in total

1.  Antioxidant properties of the edible Basidiomycete Armillaria mellea in submerged cultures.

Authors:  Ming-Yeou Lung; Yu-Cheng Chang
Journal:  Int J Mol Sci       Date:  2011-09-26       Impact factor: 5.923

Review 2.  Potential of Mushroom Compounds as Immunomodulators in Cancer Immunotherapy: A Review.

Authors:  Peter Amwoga Ayeka
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-22       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.